Open Access Open Access  Restricted Access Subscription or Fee Access

TLR-4: An Inflammatory Link to Prostate Cancer

Anjali Priyadarshini, A Chakraborti

Abstract


Prostate cancer is one of the major causes of mortality among men worldwide. The etiological factors associated with this disease are not well known. However age and ethnic origin are considered to be the major risk factors. The improved medical facilities of today have increased the life span of human; as a consequence the result is increase in disease related to geriatric population. Prostate gland is an inflammation-prone organ in the male reproductive tract and inflammatory responses have been established as an etiological agent in different types of cancer. Toll-Like Receptor-4 (TLR-4) is the key trigger of the innate immune response in the development of various inflammatory diseases. Further understanding of the function and regulation of the TLR signaling pathways in cancer may shed new lights on unraveling the mechanisms of cancer formation and progression, as well as provide new targets for more effective regimens to treat prostate cancer.

Keywords


Prostate cancer, toll like receptor, inflammation in prostate cancer

Full Text:

PDF

References


Weinberg RA, Hanahan D. The Hallmarks of Cancer. Cell. 2000; 100: 57p.

Coussens LM, Werb Z. Inflammation and Cancer. Nature (Lond). 2002; 420: 860–867p.

Mazro AM, Sutcliffe S, Platz EA, et al. Inflammation in Prostate Carcinogenesis. Nature. 2007; 7: 256–269p.

Mantovani A, Garlanda C. Inflammation and Multiplemyeloma: The Toll Connection. Leukemia. 2006; 20: 937–938p.

Kim HM, et al. Crystal Structure of the TLR4-MD-2 Complex with Bound Endotoxin Antagonist Eritoran. Cell. 2007; 130: 906–917p.

Li L. Regulation of Innate Immunity Signaling and its Connection with Human Diseases. Curr. Drugs Targets Inflamm Allergy. 2004; 3(1): 81–6p.

Chowdhury P, Sacks SH, Sheerin NS. Toll-Like Receptors TLR2 and TLR4 Initiate the Innate Immune Response of the Renal Tubular Epithelium to Bacterial Products. Clin. Exp. Immunol. 2006; 145: 346–356p.

Weindi G, Naglik JR, Kaesler S, et al. Human Epithelial Cells Establish Direct Antifungal Defense through TLR4-Mediated Signaling. J. Clin. Invest. 2007; 117: 3664–3672p.

Huang B, Zhao J, Li H, et al. Toll-Like Receptors on Tumor Cells Facilitate Evasion of Immune Surveillance. Cancer Res. 2005; 65: 5009–5014p.

Faure E, Thomas S, Xu H, et al. Bacterial LPS and IFN- Induce TLR-4 Expression in Human Endothelial Cells. J. Immunol. 2001; 166: 2018–2024p.

Kopp EB, Medzhitov R. The Toll Receptor Family and Control of Innate Immunity. Curr. Opin. Immunol. 1999; 11: 13–18p.

Child NJ, Yang IA, Pulletz MC, et al. Polymorphisms in Toll-Like Receptor 4 and the Systemic Inflammatory Response Syndrome. Biochem Soc Trans. 2003; 31: 652–653p.

Lorenz E, Mira JP, Cornish KL, et al. A Novel Polymorphism in the Toll-Like Receptor 2 Gene and its Potential Association with Staphylococcal Infection. Infect Immun. 2000; 68: 6398–401p.

Kiechl S, Lorenz E, Reindl M, et al. Toll-Like Receptor 4 Polymorphisms and Atherogenesis. N Engl J Med. 2002; 347: 185–92p.

Zheng SL, Augustsson-Balter K, Chang B, et al. Sequence Variants of TLR-4 are Associated with Prostate Cancer Risk: Results from the Cancer Prostate in Sweden Study. Can. Res. 2004; 4: 2918–2922p.

Chen YC, Giovannucci E, Lazarus R, et al. Sequence Variants of Toll-Like

Receptor 4 and Susceptibility to Prostate Cancer. Cancer Res. 2005; 65: 11771–11778p.

Karin M, Greten FR. NF-κB: Linking Inflammation and Immunity to Cancer Development and Progression. Nat. Rev. Immunol. 2005; 5: 749–759p.

Karin M, Lawrence T, Nizet V. Innate Immunity Gone Awry: Linking Microbial Infections to Chronic Inflammation and Cancer. Cell. 2006; 124: 823–835p.

Conti B, Tabarean I, AndréI C, et al. Cytokines and Fever. Front Biosci. 2004; 9: 1433–1449p.

Cheng J, Cao W, Steinberg RH, et al. PGE2 Induces VEGF and Basic Fibroblast Growth Factor mRNA Expression in Cultured Rat Muller Cells. Investig. Opthalmol. Vis. Sci. 1998; 39: 581–591p.

Gupta S, Afaq F, Mukhtar H. Involvement of Nuclear Factor-Kappa B, Bax and Bcl-2 in Induction of Cell Cycle Arrest and Apoptosis by Apigenin in Human Prostate Carcinoma Cells. Oncogene. 2002; 21: 3727–38p.

Karin M, Cao Y, Greten FR. NF-κB in Cancer: From Innocent Bystander to Major Culprit. Nat. Rev. Cancer. 2002; 2: 301–310p.

Smith MF Jr, Mitchell A, Li G, et al. Toll-Like Receptor (TLR) 2 and TLR5, but not TLR4, are required for Helicobacter Pylori-Induced NF-Kappa B Activation and Chemokine Expression by Epithelial Cells. J Biol Chem. 2003; 278: 32552–60p.

Luo JL, Kamata H, Karin M. IKK/NF-κB Signaling: Balancing Life and Death-A New Approach to Cancer Therapy. J. Clin. Invest. 2005; 2625–2632p.

Parkin DM, Whelan SL, Ferlay J, et al. Cancer Incidence in Five Continents. Vol VII. Lyon: IARC Sci Publ. 1997.

Heyen JR, Ye S, Finck B, et al. Johnson RW. Interleukin (IL)-10 Inhibits IL-6 Production in Microglia by Preventing Activation of NF-Kappa B. Brain Res Mol Brain Res. 2000; 77: 138–147p.

Dennis LK, Dawson DV. Meta-Analysis of Measures of Sexual Activity and Prostate Cancer. Epidemiology. 2002; 13: 72–75p.

Dennis LK, Lynch CF, Torner JC. Epidemiologic Association between Prostatitis and Prostate Cancer. Urology. 2002; 60: 78–83p.

Priyadarshini A, Chakraborti Mandal AK, Singh SK. Asp299Gly and Thr399Ile Polymorphism of TLR-4 Gene in Patients with Prostate Cancer from North India. Indian J of Urology. 2013; 29(1): 37–41p.

Akira S, Hemmi H. Recognition of Pathogen Associated Molecular Patterns by TLR Family. Immunol. Lett. 2003; 85: 85–95p.

Check W. Innate Immunity Depends on TLR’s. ASM News. 2004; 70: 317–322p.

Medzhitov R, Janeway C Jr. Innate Immunity. N. Engl. J. Med. 2000; 343: 338–44p.

Yarovinsky F, et al. TLR11 Activation of Dendritic Cells by a Protozoan Profilin-Like Protein. Science. 2005; 308: 1626–1629p.

Takeda K, Kaisho T, Akira S. Toll-Like Receptors. Annu Rev Immunol. 2003; 21: 335–376p.

Lemaitre B, Nicolas E, Michaut L, et al. The Dorsoventral Regulatory Gene Cassette Spatzle/Toll/Cactus Controls the Potent Antifungal Response in Drosophila Adults. Cell. 1996; 86: 973–83p.

Hoffmann JA. The Immune Response of Drosophila. Nature. 2003; 426: 33–38p.

Medzhitov R, et al. A Human Homologue of the Drosophila Toll Protein Signals Activation of Adaptive Immunity. Nature. 1997; 388: 394–402p.

Schumann RR, et al. Structure and Function of Lipopolysaccharide Binding Protein. Science. 1990; 249: 1429–31p.

Beutler B, Milsark IW, Cerami A, et al. Passive Immunization Against Cachectin/Tumor Necrosis Factor (TNF) Protects Mice from the Lethal Effect of Endotoxin. Science. 1985; 229: 869–871p.

Tracey KJ, Beutler B, Lowry SF, et al. Shock and Tissue Injury Induced by Recombinant Human Cachectin. Science. 1986; 234: 470–474p.

Arbour NC, Lorenz E, Schutte BC, et al. TLR4 Mutations are Associated with Endotoxin Hyporesponsiveness in Humans. Nat Genet. 2000; 25: 187–191p.

Lorenz E, Hallman M, Marttila R, et al. Association between the Asp299Gly Polymorphisms in the Toll-Like Receptor 4 and Premature Births in the Finnish Population. Pediatr Res. 2002; 52: 373–76p.

Ameziane N, Beillat T, Verpillat P, et al. Association of the Toll-Like Receptor 4 Gene Asp299Gly Polymorphism with Acute Coronary Events. Arterioscler Thromb Vasc Biol. 2003; 23: 61–64p.

Hawn TR, Verbon A, Janer M, et al. Toll-Like Receptor 4 Polymorphisms are Associated with Resistance to Legionnaires’ Disease. Proc Natl Acad Sci USA. 2005; 102: 2487–2489p.

Mockenhaupt FP, Cramer JP, Hamann L, et al. Toll-Like Receptor (TLR) Polymorphisms in African Children: Common TLR-4 Variants Predispose to Severe Malaria. Proc Natl Acad Sci USA. 2006; 103: 177–182p.

Sun J, Wiklund F, Zheng SL, et al. Sequence Variants in Toll-Like Receptor Gene Cluster (TLR6-TLR1-TLR10) and Prostate Cancer Risk. J Natl Cancer Inst. 2005; 97: 525–532p.

Iwasaki A, Medzhitov R. Toll Like Receptor Control of the Adaptive Immune Responses. Nat Immmunol. Oct 2004; 5(10): 987–95p.

Zarember KA, Godowski PJ. Tissue Expression of Human Toll-Like Receptors and Differential Regulation of Toll-Like Receptor mRNAs in Leukocytes in Response to Microbes, Their Products, and Cytokines. J. Immunol. 2002; 168: 554–561p.

Takeda K, Akira S. Toll-Like Receptors in Innate Immunity. Int. Immunol. 2005; 17(1): 1–14p.

Kelly MG, Alvero AB, Chen R, et al. TLR-4 Signaling Promotes Tumor Growth and Paclitaxel Chemoresistance in Ovarian Cancer. Cancer Res. 2006; 66: 3859–3868p.

He W, Liu Q, Wang L, et al. TLR4 Signaling Promotes Immune Escape of Human Lung Cancer Cells by Inducing Immunosuppressive Cytokines and Apoptosis Resistance. Mol Immunol. 2007; 44: 2850–2859p.

Chen R, Alvero AB, Silasi DA, et al. Molecular Typing of Epithelial Ovarian Cancer: Implications on Chemoresponse and Tumor Progression. J Clin Invest. 2007.

Baniyash M. Chronic Inflammation, Immunosuppression and Cancer: New Insights and Outlook. Semin. Cancer Biol. 2006; 16: 80–88p.

Bohnhorst J, Rasmussen T, Moen S, et al. Toll-Like Receptors Mediate Proliferation and Survival of Multiple Myeloma Cells. Leukemia. 2006; 20: 1138–1144p.

Du M, Roy KM, Zhong L. et al. VEGF Gene Expression is Regulated Post-Transcriptionally in Macrophages. FEBS J. 2006; 273: 732–745p.

Akira S, Takeda K, Kaisho T. Toll-Like Receptors: Critical Proteins Linking Innate and Acquired Immunity. Nat Immunol. 2001; 2: 675–680p.

Akira S, Takeda K. Toll-Like Receptor Signalling. Nat Rev Immunol. 2004; 4: 499–511p.

Tarta Kovsky B, Kovacs EJ, Takacs L, et al. T Cell Clone Producing IL-1 Activity after Stimulation by Antigen Presenting B-Cell. J. Immunol. 1986; 131: 221–228p.

Fan Fan SO, Liu W, et al. Interleukin 1 Regulates Angiopoietin-1 Expression in Human Endothelial Cells. Cancer Res. 2004; 3186–3190p.

Voronov E, Shouval DS, Krelin, et al. IL-1 is required for Tumor Invasiveness and Angiogenesis. Proc. Natl. Acad. Sci. USA. 2003; 100: 2645–2650p.

Song J, Kim D, Kim C, et al. The Association between Toll-Like Receptor 4 (TLR4) Polymorphisms and the Risk of Prostate Cancer in Korean Men. Cancer Genet Cytogenet. 2003; 190: 88–92p.

Herschman HR. Primary Response Genes Induced by Growth Factors and Tumor Promoters. Ann. Rev. Biochem. 1991; 60: 281–287p.

Liu XH, Kirschenbaum A. Inhibition of COX-2 Suppresses Angiogenesis and the Growth of Prostate Cancer in vivo. J. Urology. 2000; 164: 820–825p.

Tsujii M, Kawano S, Tsujii S, et al. Cyclo-Oxigenase Regulates Angiogenesis Induced by Colon Cancer Cells. Cell. 1998; 93: 405–409p.

Schmedtji JF Jr, Liu YS, DuBois RN, et al. Hypoxia Induces COX-2 via the NF-B p65 Transcription Factor in Human Vascular Endothelial Cells. J. Biol. Chem. 1997; 272: 601–605p.

Chung IB, Yelian FD, Zaher FM. Expression and Regulation of VEGF in the 1’st Trimester Trophoblast Cell Line. Placenta. 2000; 21: 320–324p.




DOI: https://doi.org/10.37628/ijmb.v1i1.22

Refbacks

  • There are currently no refbacks.